# A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment f

Source: https://onco.cc/trials/nct07739186/  
OnCo record `nct07739186` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of izalontamab brengitecan, tislelizumab, pemetrexed, carboplatin and other drugs in lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., not yet recruiting.

## Summary

A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) is a phase 2/3, randomised interventional study registered as NCT07739186 by Sichuan Baili Pharmaceutical Co., Ltd., with a registry enrolment figure of 120 participants, started 2026-08 and due to reach its primary completion in 2029-12. Interventions recorded: BL-B01D1; PD-1/VEGF Bispecific Antibody; Tislelizumab; Pemetrexed; Carboplatin; Cisplatin. Conditions listed: Non-squamous Non-small Cell Lung Cancer. Primary outcome: Phase II: Objective Response Rate (ORR); Phase II: Investigator-assessed Progression-free Survival (PFS); Phase III: BICR-assessed Progression-free Survival (PFS). Lung eligibility wording from the registry: "Patients with locally advanced non-squamous non-small cell lung cancer;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07739186
- Phase: 2/3
- Setting: A Randomized, Open-label, Multicenter Phase II/III Clinical Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT07739186: https://clinicaltrials.gov/study/NCT07739186

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Izalontamab brengitecan](https://onco.cc/drugs/izalontamab-brengitecan/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07739186.json